Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
11 hedge funds and large institutions have $4.5M invested in Aridis Pharmaceuticals Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
248% more capital invested
Capital invested by funds: $1.29M → $4.5M (+$3.21M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
38% more funds holding
Funds holding: 8 → 11 (+3)
5.31% more ownership
Funds ownership: 2.05% → 7.36% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
+$924K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$614K |
| 3 |
BlackRock
New York
|
+$7.54K |
| 4 |
Citigroup
New York
|
+$5.24K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$80K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$915 |
ARDS Hedge Fund Activity: Q4 2020 in Review
11 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2020, worth a combined $4.5M — up 248% from $1.29M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ARDS positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Minot Wealth Management, opening a new position worth an estimated $924K. The largest seller was Millennium Management, exiting entirely with an estimated $80K sold.
- 11 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2020, up from 8 in Q3 2020.
- Funds reported $4.5M of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2020, up 248% quarter-over-quarter.
- 5 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2020 and 2 closed out, a net change of +3 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2020 was Minot Wealth Management, an estimated $924K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2020 was Millennium Management, an estimated $80K sold.
Based on aggregated 13F filings for Q4 2020.